Clinical Trials in Middlesex, United Kingdom

7 recruiting

Showing 18 of 8 trials

Recruiting
Phase 3

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Head and Neck Squamous Cell Carcinoma
Merus B.V.500 enrolled207 locationsNCT06496178
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 2Phase 3

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics650 enrolled125 locationsNCT06788990
Recruiting
Phase 3

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 3

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Advanced Melanoma
Immunocore Ltd540 enrolled82 locationsNCT05549297
Recruiting
Phase 3

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Endometrial Cancer
BioNTech SE480 enrolled80 locationsNCT06340568
Recruiting
Not Applicable

Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers

CancerColorectal NeoplasmsMagnetic Resonance Imaging+2 more
Imperial College London244 enrolled16 locationsNCT02222844
Recruiting

Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer

Colorectal, Cancer
Royal Marsden NHS Foundation Trust1,000 enrolled71 locationsNCT04050345